Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.23)
# 2,835
Out of 5,149 analysts
112
Total ratings
41.41%
Success rate
-1.8%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Buy | $15 → $20 | $6.95 | +187.77% | 5 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Buy | $220 → $230 | $184.02 | +24.99% | 22 | Feb 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.30 | +154.90% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $33.78 | +6.57% | 5 | Jan 5, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.91 | +169.36% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $131.14 | +25.06% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.69 | +279.40% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.58 | +558.91% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.03 | +854.27% | 6 | Aug 18, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $4.01 | +573.32% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.07 | +194.84% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.60 | +4,900.00% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.50 | +46.67% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $10.67 | +1,305.81% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $32.28 | - | 2 | Jan 31, 2017 |
COMPASS Pathways
Feb 18, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $6.95
Upside: +187.77%
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $220 → $230
Current: $184.02
Upside: +24.99%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.30
Upside: +154.90%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $33.78
Upside: +6.57%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.91
Upside: +169.36%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $131.14
Upside: +25.06%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.69
Upside: +279.40%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.58
Upside: +558.91%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.03
Upside: +854.27%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.01
Upside: +573.32%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.07
Upside: +194.84%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.60
Upside: +4,900.00%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.50
Upside: +46.67%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $10.67
Upside: +1,305.81%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $32.28
Upside: -